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EmphysemaAbstract Cigarette smoking has a destructive effect on the extracellular matrix (ECM), so it is con-
sidered the most important risk factor for the development of emphysema as it leads to recruitment
of activated macrophages and neutrophils in the lung leading to release of proteolytic enzymes as
matrix metalloproteinases (MMPs) or an imbalance between MMPs and the tissue inhibitors of
MMP (TIMPs), playing a role in the pathogenesis of emphysema.
Aim of the work: The aim of this work was to evaluate the level of MMP-9 and tissue TIMP-1 in
bronchoalveolar lavage of apparently healthy smokers.
Methods and results: MMP-9 and TIMP-1 levels were measured by ELISA in BAL in 10 healthy
controls, 15 apparently healthy smokers and 15 emphysematous patients. Smokers and COPD
patients had a higher concentration of MMP-9 and TIMP-1 compared with controls. The ratio
of MMP-9 to TIMP-1 was signiﬁcantly higher in the emphysema group than the two other groups.
Also the smoker group was higher than the control group but without statistic signiﬁcant difference.
Conclusions: Healthy smokers had a higher concentration of total MMP-9 and that concentra-
tion was correlated with their exposure to tobacco smoke. Maintenance of normal MMP-9/TIMP-1
ratio in healthy smokers may explain the absence of progressive airway obstruction. Measurement
of active MMP-9 concentration could be useful for assessment of airway remodeling.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Airway inﬂammation of emphysematous patients appears to
be an ampliﬁcation of the normal inﬂammatory response ofd.
372 A.M. Abdella et al.respiratory tract to chronic irritants such as cigarette smoke
which is the major risk factor for emphysema. This ampliﬁca-
tion is attributed to two mechanisms oxidative stress and
excess of proteinases in the lung [1].
The extracellular matrix (ECM) is a dynamic structure and
equilibrium between synthesis and degradation of ECM is
required for maintenance of its homeostasis [2].
Matrix metalloproteinases (MMPs) can degrade any of
matrix constituents such as collagen, elastin, basement mem-
brane, laminin, and ﬁbronectin. The balance between MMPs
and their inhibitors is critical in tissue repair and remodeling
and its disturbance plays an important role in the pathogenesis
of emphysema [3].
One of macrophage-derived MMPs is MMP-9 which is
capable of degrading type IV collagen. It is present in low
quantities in healthy lung, but much more abundant in several
lung diseases, including COPD, asthma and IPF [4].
Macrophage also produces tissue inhibitors of metallopro-
teinases (TIMPs), which bind to the active forms of MMPs. In
addition, TIMP-1 binds to pro-MMP-9 [5].
Several studies suggest that the balance between regulated
macrophage MMP-9 and TIMP-1 plays a key role in cigarette
smoke induced emphysema, which may be an important deter-
minant of clinical expression of COPD as emphysematous
patients show increased expression of MMP-9 [6]. The two
main elastase producing cell types in the airways of smokers
are neutrophils and macrophages, but macrophages are by
far the most abundant cell type in the bronchoalveolar spaces
in cigarette smokers. This may suggest a positive correlation
between MMP-9 activity and the degree of air ﬂow limitation.
This makes smokers have a higher prevalence of respiratory
symptoms, lung function abnormalities, and greater COPD
mortality rates than nonsmokers [7].
Emphysema is characterized by speciﬁc inﬂammatory cells
involving neutrophils, macrophages and lymphocytes. These
cells release inﬂammatory mediators (chemotactic factors) that
can attract more inﬂammatory cells, amplify the inﬂammatory
process [8].Aim of the work
The aim of this work was to evaluate the levels of MMP-9 and
TIMP-1 in the BAL in apparently smokers in comparison to
emphysematous patients.Table 1 Comparison of mean value of some spirometric data
between studied groups.
Variables Group I Group II Group III F p
FEV1% of predicted
Range 95–98% 87.5–94% 60–84% 20.362 0.001*
Mean 96.35 90.13 73.2
SD ±1.22 ±2.21 ±7.77
FVC% of predicted
Range 97–110% 70–100% 63–95% 8.133 0.001*
Mean 98.1 94.16 79.06
SD ±7.70 ±22.47 ±4.96
FEV1/FVC% of actual
Range 80–89% 79–85% 50–70% 16.388 0.001*
Mean 82.6 81.3 69.1
SD ±2.7 ±2.3 ±3.5
* Signiﬁcant p value <0.05.Subjects and methods
This work was carried out in the Chest Department, Tanta Uni-
versity Hospital on 40 male subjects; during the period from
February 2012 to June 2013. They were classiﬁed into 3 groups.
Group I: Included 10 apparently healthy non smoker volun-
teers, their ages ranged from 45 to 55 years (control group).
Group II: Included 15 apparently healthy smoker volun-
teers, their ages ranged from 44 to 59 years, with smoking
index ranging from 7 to 20 pack/year (smoker group).
Group III: Included 15 of emphysematous patients and their
ages ranged from 48 to 65 years. Their smoking index ran-
ged from 13 to 22 pack/year. (COPD group).Written consent was obtained from all participants in this
research.
Inclusion criteria of mild–moderate emphysema
Severity was assessed according to Global Initiative for
Chronic Obstructive Pulmonary Disease (GOLD 2011).
Patients group A: Low risk, less symptoms. Typically
GOLD 1 or GOLD 2 (Mild: FEV1/FVC ratio < 70%, and
FEV1P 80% predicted, or Moderate: FEV1/FVC
ratio < 70%, and 50% 6 FEV1 < 80% predicted) and/or 0–
1 exacerbation per year and mMRC grade 0–1.
Patient group B: Low risk, more symptoms. Typically
GOLD 1 or GOLD 2 and/or 0–1 exacerbation per year and
mMRC gradeP 2.
Exclusion criteria
Patients with upper or lower respiratory tract infection during
the last 2 months preceding the study or associated bronchiec-
tasis, bronchial asthma, lung cancer, known a1-antitrypsin
deﬁciency, acute exacerbation in the 4 weeks preceding the
study and patients with respiratory failure, heart failure or
any other organ failure.
Methods
The following were done for all subjects.
Thorough history taking, complete general and local exam-
ination, chest X-ray, CBC, CT scan for emphysematous
patients to detect mild emphysematous changes in early cases
and exclude any other pathology, pulmonary function tests
including FVC, FEV1, and FEV1/FVC before and after inha-
lation of B2 agonist. Bronchoalveolar lavage (BAL) was done
via ﬁberoptic bronchoscope for all groups, the collected BAL
was centrifuged for 10 minutes measured for BAL total and
differential cell count. The supernatant was stored at 80 C
until later examination for estimation of gelatinase B (MMP-
9) and (TIMP-1) by ELISA technique.
Results
The mean value and SD of FEV1, FVC, and FEV1% were
signiﬁcantly lower in the COPD group than the smoker and
Figure 1 Mean values of spirometric data in the three studied groups.
Table 2 Comparison of mean values of BAL total and
differential leukocytic count between studied groups.
Variables Group I Group II Group III F p
TLC · 103
Range 100–140 170–230 230–490 9.36 0.002*
Mean 121.9 199.3 370.6
SD ±12.67 ±15.79 ±84.45
AM%
Range 80–86% 87–92.7% 90–95% 3.17 0.005*
Mean 82.74 89.98 92.54
SD ±1.97 ±1.91 ±1.43
Neutrophil%
Range 2–3% 2–10% 4–7% 5.14 0.001*
Mean 2.7 5.06 6.53
SD ±0.48 ±0.90 ±2.07
Lymphocytes%
Range 10–15.3% 6–9% 1–4% 6.37 0.003*
Mean 15.13 5.03 2.04
SD ±2.01 ±1.07 ±0.84
Eosinophils%
Range 0.3–2% 0–0.8% 0–0.5 4.14 0.58
Mean 1.03 0.39 0.24
SD ±0.57 ±0.25 ±0.13
* Signiﬁcant p value <0.05.
Figure 2 Mean value of BAL total leukocytic count · 103 in the
three studied groups.
Table 3 Comparison of mean values ± SD of BAL MMP-9
concentration in the three studied groups.
BAL MMP-9 concentration in pg/ml
GI GII GIII
Range 1500–4600 7200–10,500 11,160–33,560
Mean 2731 8948 18,484
±SD 344.8 959.9 475.2
F test 11.225
p value 0.001
Scheﬀe test
GI&GII GI&GIII GII&GIII
T 4.58 2.5 6.35
P 0.003* 0.001* 0.001*
* Signiﬁcant p value < 0.05.
MMP-9 and TIMP-1 in BAL of healthy smokers 373control groups. Also the smoker group was lower than
the control but there was no statistically signiﬁcant
difference between them as we selected apparently healthy
smokers.
The mean value and SD of BAL TLC, macrophage%,
neutrophil%, were signiﬁcantly higher in smoker and COPD
groups than the control group.
The mean value and SD of BAL MMP-9 and TIMP-1 con-
centration showed signiﬁcant increase in the smoker and
emphysema groups than the control group. The mean value
and SD of BAL MMP-9/TIMP-1 ratio were signiﬁcantly
higher in the emphysema group than the two other groups,
Also the smoker group was higher than the control group
but without statistic signiﬁcant difference.
Figure 3 BAL MMP9 (pg/ml) in the three studied groups.
Table 4 Comparison of mean values ± SD of BAL TIMP-1
concentration in the three studied groups.
BAL TIMP-1 concentration in pg/ml
GI GII GIII
Range 1500–5000 5000–9500 6000–25000
Mean 2930 7220 15,139
±SD 458.3 1453.3 5082.7
F test 3.314
p value 0.001
Scheﬀe test
GI&GII GI&GIII GII&GIII
T 4.45 2.91 6.65
p 0.003* 0.001* 0.009*
* Signiﬁcant p value <0.05.
Figure 4 BAL TIMP-1 (pg/ml) in the three studied groups.
Table 5 Comparison of mean values ±SD of BAL MMP-9/
TIMP-1 ratio in the three studied groups.
BAL MMP-9/TIMP-1
GI GII GIII
Range 0.6–1.31 0.93–1.53 1.27–2.52
Mean 0.97 0.95 1.86
±SD 0.21 0.18 0.37
F test 15.417
p value 0.001
Scheﬀe test
GI&GII GI&GIII GII&GIII
T 1.2 5.91 7.02
p *0.162 *0.001 *0.004
* Signiﬁcant p value <0.05.
Figure 5 MMP-9/TIMP-1 ratio in the three studied groups.
374 A.M. Abdella et al.Correlation of MMP-9 and TIMP-1 concentration in BAL and
other studied parameters
- MMP-9 and TIMP-1 concentration in BAL had a signiﬁ-
cant positive correlation with smoking index, BAL total cell
count, BAL macrophage% and BAL neutrophils%.- MMP-9 and TIMP-1 concentration in BAL had a signiﬁ-
cant negative correlation with FEV1, FVC, and FEV1/
FVC and BAL lymphocytes%.Correlation of MMP-9/TIMP-1 ratio in BAL and some studied
parameters
- There was a signiﬁcant positive correlation between BAL
MMP-9/TIMP-1 ratio and smoking index, BAL total cell
count and BAL macrophage%.
Figure 7 Correlation between BAL TIMP and smoking index.
Figure 6 Correlation between BAL MMp-9 and smoking index.
MMP-9 and TIMP-1 in BAL of healthy smokers 375- There was a signiﬁcant negative correlation between BAL
MMP-9/TIMP-1 ratio and FEV1 (Tables 1–5, Fig. 1–7).
Discussion
Cigarette smoking has a destructive effect on the ECM. It
leads to recruitment of macrophages and neutrophils in the
lung leading to release of proteolytic enzymes leading to colla-
gen and elastin degradation. These structural changes alter the
(protease–antiprotease) balance in the lung particularly matrix
metalloproteinases (MMPs), a large family of proteolytic
enzymes that degrade the components of ECM are implicated
in pulmonary remodeling processes that underlie emphysema
[9,10].
Pulmonary functions studies
In the present study it was found that the Pulmonary function
parameters (FEV1, FVC and FEV1/FVC) were signiﬁcantly
lower in apparently healthy smokers and emphysematous
patients compared to healthy non smokers.
The ﬁndings of the present study are in consistence with
many authors, who found that pulmonary function data were
lower in smokers when compared with non smokers [11].
Boskabady et al. (2011) found signiﬁcant negative correla-
tions between smoking duration and the values of pulmonaryfunctions [12]. Atef et al. (2002) concluded that smoking leads
to increased respiratory symptoms and reduction of pulmon-
ary functions values [13].
The airways of smokers have a number of structural abnor-
malities including mucus plug accumulation, squamous meta-
plasia, inﬂammatory cellular inﬁltration, smooth muscle
hypertrophy, mucosal metaplasia and submucosal hyperplasia
all these changes lead to airﬂow obstruction and increased
respiratory symptoms [14].
Fletcher et al., in an 8-year prospective study showed that
the average decline in FEV1 in smokers is (60 ml/yr) faster
than in nonsmokers (30 ml/yr). However, only 15–20% of
smokers develop clinically signiﬁcant COPD have an average
decline in FEV1 of greater than 60 ml/yr [15].Total and differential leukocytic count in BAL
Neutrophils secrete proteases, including neutrophil elastase
(NE), cathepsin G, and proteinase-3, as well as matrix metallo-
proteinases as MMP-8 and MMP-9, which are responsible for
alveolar destruction. Neutrophil survival in the respiratory
tract may be increased by cytokines, such as granulocyte- mac-
rophage colony stimulating factor (GM-CSF) and granulocyte
colony stimulating factor. Smoking has direct stimulatory
effect on granulocyte production and release from bone mar-
row, possibly mediated by (GM-CSF) released from lung mac-
rophages [16].
376 A.M. Abdella et al.In the present study signiﬁcant increase was found in BAL
total cell count, neutrophils% and macrophages% in appar-
ently healthy smokers and emphysematous patients compared
with control.
The present study results agree with Skold et al. (2006) who
reported signiﬁcant increase in neutrophil and macrophage
numbers in BAL of healthy smokers and emphysematous
patients compared to healthy non smokers [17].
The present study is in consistence with El Shimmy et al.
(2010), who studied inﬂammatory cells in BAL of 22 mild non-
smoker asthmatic patients, 22 ex smoker mild COPD patients
and 12 healthy nonsmoker volunteers and found that the BAL
total cell count as well as macrophage% was signiﬁcantly
higher in COPD patients when compared with asthmatics
and control groups [18].
Gammble et al. (2007), studied inﬂammatory cells in BAL
of 20 COPD patients, they found that neutrophil count was
signiﬁcantly increased in BAL of COPD patients when com-
pared to control [19].
Also EL Hussiny et al. (1994) found that lymphocyte per-
cent was signiﬁcantly decreased in COPD patients when com-
pared to the control group. This can be explained by the
pathology of COPD which mainly affects the small airways
more than the large airways with the sequestration of lympho-
cytes in these small airways so their yield in BAL was difﬁcult
to obtain [20].MMP-9 and TIMP-1 and their ratio in BAL
MMP-9 is secreted as an inactive pro-enzyme that is subse-
quently activated by several mechanisms including enzymatic
cleavage [21].
TIMP-1 has been described as an MMP-9 activity inhibitor
by binding to its precursors and active form [22]. The previous
studies have shown increased sputum MMP-9 and TIMP-1
concentrations and alveolar macrophages trigger larger
amounts of MMP-9 with greater enzymatic activity in COPD
patients. [23]. Another research showed a positive correlation
between MMP-9/TIMP-1 ratio and airway obstruction
assessed by FEV1 measurement [24].
In the normal individuals the MMP-9 is secreted with
TIMP-1 in 1:1 ratio. The imbalance of this ratio is the main
determinant factor in the pathogenesis of emphysema [23].
In the present study the mean values of BAL MMP-9 and
TIMP-1 concentrations showed a signiﬁcant increase in the
smoker and emphysema groups than the control group. Lim
and coworkers (2005) demonstrated that alveolar macro-
phages obtained from BAL in current healthy smokers
released greater amount of MMP-9 and TIMP-1 compared
with non-smokers [25]. Betsuyaku et al. (2002) demonstrated
signiﬁcantly higher levels of MMP-9 and MMP-8 in BAL in
current smokers with emphysema than in those without
emphysema [26].
Kang et al. (2003) found that MMP-9 expression in human
lung parenchyma is associated with cigarette smoking and
also with the obstruction of airﬂow, suggesting that MMP-9
may play a role in the pathogenesis of cigarette smoke-
induced airﬂow obstruction in COPD [27]. Vernooy et al.
(2004), used immuno-captured assays to quantify the activity
of MMP collagenase (MMP-1, MMP-8, MMP-13) and MMP
gelatinase (MMP-2, MMP-9) in the induced sputum of 17COPD patients and 17 healthy smokers. The levels of total
and active MMP-9 were high in both groups; it was signiﬁ-
cantly higher in the COPD group when compared to smokers.
MMP-9 activity was strongly related to neutrophilia in both
groups. [28]. Culpitt et al. (2005) compared MMP- proﬁles
in the airways of nonsmokers, healthy smokers and COPD
patients. Induced sputum was assessed for MMP-1,-2,-3,-8,
and -9, and TIMP-1 by ELIZA. COPD patients had high lev-
els of MMP-1,-8 and-9 compared to the other groups. MMP-
9 activity was elevated in COPD sputum by about 3–12 fold
above the other groups [29]. Finlay and coworkers (1997)
demonstrated that the secretion of MMP-1 and MMP-9 were
increased in the alveolar macrophages from emphysematous
patients [30]. Ohnishi et al. (1998), reported that the elastolyt-
ic activities of MMP-2 and MMP-9 were increased from
emphysematous lung tissues when compared with non emphy-
sematous one [31].
Zamzam et al. (2005) demonstrated that high concentration
of MMP-9 was found in BAL of 20 COPD patients when com-
pared to 10 healthy controls, while in contrary to the present
study, the level of TIMP-1 in BAL of COPD patients showed
no statistical difference when compared with controls [32].
This may be explained by the fact that the AM from non-
smokers released more TIMP-1 at baseline than cells from
either healthy smokers or COPD patients. While AM of smok-
ers and COPD patients produced more TIMP-1 in response to
CSM stimulation than AM from healthy nonsmokers [6].
In the present study The ratio of BALMMP-9/TIMP-1 was
signiﬁcantly higher in the emphysema group than the two
other groups, also the smoker group was higher than the con-
trol group but without statistically signiﬁcant difference.
In consistence with the present study, Avile´s B et al. (2006)
demonstrated that when the ratio of active MMP-9 to TIMP-1
was calculated, the group of patients with emphysema contin-
ued to display a higher ratio compared with the other groups.
This higher ratio is indicative of a reduced availability of
TIMP-1 per molecule of MMP-9 and, therefore, a greater pre-
disposition to tissue damage which would favor remodeling.
However, the ratio in healthy smokers was reduced to a level
relatively non signiﬁcant compared to the control group. This
may indicate that healthy smokers, despite the differences in
the total concentrations of the enzymes, maintain the same
equilibrium as the control group [33].
Vignola et al. (2004) demonstrated that sputum elastase and
the MMP-9/TIMP-1 ratio were associated with the magnitude
of high resolution CT scan abnormalities of the lung paren-
chyma in emphysema [34].
In the present study there was a signiﬁcant positive correla-
tion between BAL MMP-9, TIMP-1 and MMP-9/TIMP-1 and
smoking index. The ﬁndings of the present study are consistent
with Kang et al. (2003) who revealed that the ratio of MMP-9
to TIMP-1 was positively correlated with the amount of ciga-
rette smoked [27].
Several studies have shown that cigarette smoking causes
an inﬂammatory process in central airways, peripheral air-
ways, and lung parenchyma leading to the accumulation of
various inﬂammatory cells including macrophages and neutro-
phils that are well known to produce MMP-9 which increase
airways’ response to various oxidative stress and inﬂammatory
cytokines caused by cigarette smoking as lipopolysaccharide,
interleukin-1b, and tumor necrosis factor-a (TNF a) [35–37].
These ﬁndings suggest that pro-inﬂammatory activity induced
MMP-9 and TIMP-1 in BAL of healthy smokers 377by smoking might regulate MMP-9 activity in the COPD air-
ways [38,39].
In the present study there were signiﬁcant negative correla-
tions between BAL MMP-9 and TIMP-1 concentrations and
pulmonary functions (FEV1% of predicted, FVC% of pre-
dicted and FEV1/FVC% of actual). And there was a signiﬁ-
cant negative correlation between MMP-9/TIMP-1 ratio and
FEV1.
These results are consistent with Avile´s et al. who found
that there was a negative correlation between MMP-9 concen-
tration and the ventilatory functions (FEV1, FVC, FEV1/
FVC), also they found that MMP-9/TIMP-1 ratio had a signif-
icant negative correlation with FEV1% which was even stron-
ger than each parameter separately [33].
Beeh et al. also found that MMP-9/TIMP-1 ratio was cor-
related negatively with the severity of airway obstruction
(FEV1% of predicted) [23].
Contrary to the present study El Shimmy et al. (2010)
found no signiﬁcant correlation between MMP-9 and TIMP-
1 and the ventilatory functions (FEV1, FVC, FEV1/FVC).
This may be explained by the fact that they had conducted
their study on mild degree COPD patients; also they did not
study the effect of smoking [18].
In the present study a signiﬁcant positive correlation was
found between BAL MMP-9, TIMP-1, MMP-9/TIMP-1 and
total cell count, macrophage% and neutrophil% while there
was a signiﬁcant negative correlation with lymphocytes%.
Sarah et al. (2002), [40] demonstrated that alveolar macro-
phages (AM) are a signiﬁcant source of MMP-9 in the airways
of COPD patients.
The present study is consistent with El Shimmy et al. (2010)
who found that there was a negative correlation between
MMP-9 and BAL lymphocytes% which may be explained by
the increased percentages of the other cell types.[18].
Few studies have analyzed the concentration of TIMP-1
and the results obtained have been inconsistent. Avile´s et al.
(2006) found that the concentrations of TIMP-1 found in
patients with COPD were signiﬁcantly lower than in the group
of healthy smokers and, and the concentrations in healthy
smokers were lower than in the control group [33]. These
results are consistent with the results of Kang et al. (2003)
using immunochemical methods in biopsy material, where
the level of TIMP-1 was found to be lower in smokers and,
likewise, further reduced with the appearance of airway
obstruction [27]. In contrast to the results obtained in this
study, Vignola et al. (2004) reported that the production of
TIMP-1 in sputum samples from patients with COPD was
higher than in healthy subjects [34]. This difference may be
accounted for by differences in sputum processing that would
affect the results obtained from analysis of the supernatant
[41]. Furthermore, the patients included in the study by Vign-
ola et al. had less severe airway obstruction and differences in
the extent of smoking habit [34].
The few studies to have analyzed the ratio between these
markers agree that it is more representative of the extent of
remodeling than any of the measurements performed sepa-
rately [42]. In the present study, the ratio of MMP-9 to
TIMP-1 was higher in patients with COPD than in controls,
and was inversely correlated with FEV1. This higher ratio is
indicative of a reduced availability of TIMP-1 per molecule
of MMP-9 and, therefore, a greater predisposition to tissue
damage which would favor remodeling.The inﬂammatory changes and protease imbalance in
emphysema are also seen in cigarette smokers but to a lesser
extent. So healthy smokers were examined in this study before
the emphysematous patients to ﬁnd out whether the biochem-
ical abnormalities seen in patients with established emphysema
preceded the onset of the disease. Increased levels of BAL
MMP-9 in healthy smokers appear to be an early feature of
emphysema in susceptible smokers.Conﬂict of interest
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